Stock market crash: I’d buy this small-cap healthcare share

I reckon this company is in good shape for surviving and trading through the current crisis and will likely return to its growth trajectory later.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The coronavirus crisis has knocked back the share price of small-cap healthcare company Alliance Pharma (LSE: APH). At 66p, it’s around the level it was at the beginning of last autumn.

Back then, the stock had just begun its ascent from a long period of consolidation. So shareholders will likely feel frustration. But the good news is the underlying business appears to be in pretty good shape and trading well through the crisis.

Holding up well

In today’s full-year results report, chief executive Peter Butterfield explained the supply chain is “holding up well” in this crisis. But demand is “harder to forecast.” And he does anticipate lower sales from the Asia Pacific region during the first half of 2020. For now, the company is assuming a gradual recovery in that geography during the second half of the year.

Meanwhile, Butterfield reckons revenue from the UK and mainland Europe will be lower because of the crisis, “but to a lesser extent.” There’s a higher proportion of prescription medicines sold in this region, which should help the situation.

To put things in perspective, around 62% of last year’s revenue came from the UK, Ireland and mainland Europe. The rest came from other international regions. So, the hit from the effects of the coronavirus pandemic looks as if it will be limited, and most business will likely carry on through the crisis.

Alliance Pharma owns or in-licenses the rights to more than 90 consumer healthcare and pharmaceutical products and sells to more than 100 countries via a network of distributors. So, the company occupies a niche in an attractive sector. And we can see from the five-year financial and trading record that cash flow has been consistent and supportive of generally rising earnings.

Preserving cash

But the directors are being cautious and they’ve axed the full-year dividend “to prudently preserve cash” because of the pandemic. Prior to the crisis, the company had been doing a good job of raising its dividend a bit each year.

The directors’ move will disappoint some some shareholders, but I think it’s wise. The crisis is open-ended, and no one knows for sure what will happen next. Perhaps all companies should suspend their dividends. As an investor, I’d rather hold shares in a company that gives itself every chance of survival than one that weakens its finances by doling out cash it could end up needing.

For what it’s worth, today’s full-year figures are good. Revenue rose by 15% compared to a year earlier, underlying earnings per share elevated by 12% and free cash flow shot up by 81%. The net debt figure reduced by 31%. Indeed, Alliance Pharma has been growing well, both organically and via acquisitions.

I reckon the company is in good condition for surviving and trading through the crisis and will likely return to its growth trajectory later. Meanwhile, I’d be happy to pick up a few of the shares now.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kevin Godbold has no position in any share mentioned. The Motley Fool UK has recommended Alliance Pharma. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

5 steps to start buying shares with under £500

Learn how this writer would start buying shares with a few hundred pounds in a handful of steps, if he…

Read more »

Young happy white woman loading groceries into the back of her car
Investing Articles

The FTSE 100 offers some great bargains. Is this one?

Our writer digs into one FTSE 100 share that has had a rough 2024 to date, ahead of its interim…

Read more »

Smiling white woman holding iPhone with Airpods in ear
Investing Articles

£9,000 of savings? Here’s my 3-step approach to aim for £1,794 in passive income

Christopher Ruane walks through the practical steps he would take to try and turn £9,000 into a sizeable passive income…

Read more »

Group of young friends toasting each other with beers in a pub
Investing Articles

I’d buy 29,412 shares of this UK dividend stock for £150 a month in passive income

Insiders have been buying this dividend stock, which offers an 8.5% yield. Roland Head explains why he’d choose the shares…

Read more »

Red briefcase with the words Budget HM Treasury embossed in gold
Investing Articles

Could the new UK budget spell growth for these 6 FTSE stocks? I think so!

Mark David Hartley considers six UK stocks that could enjoy growth off the back of new measures announced in the…

Read more »

Investing Articles

With a 6.6% yield, is now the right time to add this income stock to my ISA?

Our writer’s looking to boost his Stocks and Shares ISA. With this in mind, he’s debating whether to buy a…

Read more »

Dividend Shares

This blue-chip FTSE stock just fell 12.5% in a day. Is it time to consider buying?

Smith & Nephew is a well-known, blue-chip FTSE stock with a decent dividend yield. And its share price just dropped…

Read more »

Investing Articles

At 72p, the Vodafone share price looks to be at least 33% undervalued to me

Our writer looks at a number of valuation measures to determine whether the Vodafone share price reflects the fair value…

Read more »